Male circumcision and Mycoplasma genitalium infection in female partners: a randomised trial in Rakai, Uganda
Tobian, A.A.R.; Gaydos, C.; Gray, R.H.; Kigozi, G.; Serwadda, D.; Quinn, N.; Grabowski, M.K.; Musoke, R.; Ndyanabo, A.; Nalugoda, F.; Wawer, M.J.; Quinn, T.C.
Sexually Transmitted Infections 90(2): 150-154
2014
ISSN/ISBN: 1472-3263 PMID: 24259189 DOI: 10.1136/sextrans-2013-051293Document Number: 577035
Previous randomised trial data have demonstrated that male circumcision reduces Mycoplasma genitalium prevalence in men. We assessed whether male circumcision also reduces M genitalium infection in female partners of circumcised men. HIV-negative men were enrolled and randomised to either male circumcision or control. Female partners of male trial participants from the intervention (n=437) and control (n=394) arms provided interview information and self-collected vaginal swabs that were tested for M genitalium by APTIMA transcription-mediated amplification-based assay. Prevalence risk ratios (PRR) and 95% CI of M genitalium prevalence in intervention versus control group were estimated using Poisson regression. Analysis was by intention-to-treat. An as-treated analysis was conducted to account for study-group crossovers. Male and female partner enrolment sociodemographic characteristics, sexual behaviours, and symptoms of sexually transmitted infections were similar between study arms. Female M genitalium prevalence at year 2 was 3.2% (14/437) in the intervention arm and 3.6% (14/394) in the control arm (PRR=0.90, 95% CI 0.43 to 1.89, p=0.78). In an as-treated analysis, the prevalence of M genitalium was 3.4% in female partners of circumcised men and 3.3% in female partners of uncircumcised men (PRR=1.01, 95% CI 0.48 to 2.12, p=0.97). Contrary to findings in men, male circumcision did not affect M genitalium infection in female partners.